Abstract
Hodgkin lymphoma (HL) survivors have an increased risk of developing subsequent treatment-related primary malignancies. In the last few decades, advances in knowledge, radiotherapy, chemotherapy and autologous stem cell transplantation have led to the transformation of lethal malignancy into highly curable malignancy, thereby improving outcomes. With prolonged survival, the risk of developing subsequent treatment-related late adverse effects, such as malignancies, steadily increases over time. Herein, we present the first case of a treatment-related second primary stage IV peripheral small cell lung carcinoma in a female HL survivor who was also diagnosed with right breast cancer 13 years after HL treatment and 1 year before her lung cancer diagnosis.
Reference19 articles.
1. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 global burden of disease study;Zhou;J Hematol Oncol,2019
2. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis;Piris;Pathology,2020
3. Adult Hodgkin Lymphoma Treatment (PDQ®)–health professional version [Internet]. National Cancer Institute, 2022. Available: https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq#_36
4. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma
5. Casciato DA , Territo MC . Hodgkins and Non-Hodgkins Lymphoma. In: Manual of clinical oncology. 7th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health, 2012: p. 520.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antineoplastics;Reactions Weekly;2022-04